Xarostat-F 10 Tablet is a combination lipid-lowering medication containing Fenofibrate 160 mg and Rosuvastatin 10 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) and total cholesterol by inhibiting the rate-limiting enzyme in cholesterol biosynthesis. The combination therapy offers a synergistic effect in improving lipid profiles, thereby reducing the risk of cardiovascular events in patients with mixed dyslipidemia or those inadequately controlled on monotherapy. Xarostat-F 10 is typically prescribed alongside lifestyle modifications including diet, exercise, and weight control. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of liver function tests and creatine kinase levels is recommended to detect potential adverse effects such as hepatotoxicity or myopathy. This medication should be used under medical supervision, particularly in individuals with a history of muscle disorders or those on concomitant lipid-lowering agents.